April 19th 2021
Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.
April 16th 2021
Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.
April 14th 2021
Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.
April 12th 2021
Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.
April 8th 2021
Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.
April 8th 2021
Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.
April 6th 2021
Brian Till, MD, discusses the utility of brexucabtagene autoleucel in mantle cell lymphoma.
April 2nd 2021
Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.
March 19th 2021
Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.